Archives: Press Releases
Modulus Discovery Announces Signing of Collaboration Agreement with Tokyo Institute of Technology
News -
09 May, 2019 -
Modulus Discovery, Inc., an early stage global biopharmaceutical company, announced today the signing of a research collaboration agreement with Professor Masahito Oue, Assistant Professor of Tokyo Institute of Technology (“Tokyo Tech”). The collaboration will focus on the implementation and scale-up of Modulus’ cutting-edge TSUBAME 3.0 is recognized as one of the world’s most efficient supercomputers, ...continuedModulus Discovery Announces Senior Appointments including Jon Mason as Scientific Advisor
News -
28 January, 2019 -
Modulus Discovery, Inc., an early stage global biopharmaceutical company, announced today the appointment of Jonathan Mason, Ph.D. as Scientific Advisor to the Company, and William Sinko, Ph.D., as Principal Scientist, Computational Drug Discovery. Dr. Mason is a global leader and scientific expert in drug discovery, particularly in the development and application of computational technologies for ...continuedModulus Discovery Announces the Initiation of a Research Collaboration with Prof. Tsutomu Suzuki, University of Tokyo
News -
31 October, 2018 -
Modulus Discovery, Inc., an early stage drug discovery company announced today the initiation of a research collaboration with Professor Tsutomu Suzuki of Department of Chemistry and Biotechnology, Graduate School of Engineering, University of Tokyo for target validation of a potential drug discovery target. Prof. Suzuki is one of the leading scientists in the field of ...continuedModulus Discovery Announces Signing of a Multi-Target Research Collaboration with Professor Osamu Nureki, University of Tokyo
News -
04 September, 2018 -
Modulus Discovery, Inc., an early stage drug discovery company announced today the signing of a multi-target research collaboration with Professor Osamu Nureki of Department of Biological Sciences, Graduate School of Science, University of Tokyo for structural analysis on several drug target proteins. Professor Nureki is a renowned structural biologist recently awarded the Purple Ribbon* from ...continuedModulus Raises 800M Japanese Yen for Its Series A Funding Round
News -
09 August, 2018 -
09 August, 2018 – Modulus Discovery, Inc., an early stage drug discovery company announced today that it has successfully raised a total of 800M Japanese Yen (approximately US $7.2M) for its series A round, led by Fast Track Initiative, Inc. (FTI) and joined by PeptiDream, Inc. (PeptiDream) and DBJ Capital Co., Ltd. (DBJ-C), the venture ...continuedModulus Announces the Appointment of Former Senior Pharma Executive, Professor Wataru Uchida, as Scientific Advisor
News -
31 July, 2018 -
Modulus Discovery, Inc., an early stage drug discovery company announced today the appointment of Wataru Uchida, Professor at the Center for Drug Discovery and Exploratory Clinical Trials, Tohoku University, as Scientific Advisor. Professor Uchida served as Head of Drug Discovery Research, Senior Corporate Executive at Astellas Pharma Inc. until March 2018, and has more than ...continuedModulus Discovery Announces the Appointment of Hiroko Nishimoto As Advisor
News -
01 June, 2018 -
Modulus Discovery, Inc., an early stage global biopharmaceutical company, announced today the appointment of Hiroko Nishimoto as Advisor to the Company. Ms. Nishimoto has more than 14 years of pharmaceutical business experience including corporate strategy, business development, external affairs, and CSR at Astellas Pharma Inc.. As a liaison of the Japan Pharmaceutical Manufacturers Association, she ...continuedModulus Discovery Announces the Appointment of Taisuke Takahashi, Ph.D. as Vice President and Head Of Chemistry
News -
01 April, 2018 -
Modulus Discovery, Inc., an early stage global biopharmaceutical company with offices in Tokyo, Japan and Cambridge, MA, announced today the appointment of Taisuke Takahashi, Ph.D., as Vice President and Head of Chemistry. Dr. Takahashi joins us from Astellas Pharma where he worked for 13 years in R&D as a medicinal chemist. During his tenure, he ...continuedModulus Discovery Announces the Appointment of Yoh Terada, Ph.D. as Chief Scientific Officer
News -
02 January, 2018 -
Modulus Discovery, Inc., an early stage global biopharmaceutical company with offices in Tokyo, Japan and Cambridge, MA, announced today the appointment of Yoh Terada, Ph.D., as Chief Scientific Officer of Modulus Discovery. Dr. Terada joins Modulus from Astellas Pharma, where he worked for nearly twenty years in various senior disease biology R&D and management capacities. ...continuedModulus Discovery Establishes Wholly Owned U.S. Subsidiary and R&D Office in Cambridge, MA
News -
15 December, 2017 -
Modulus Discovery, Inc., an early stage drug discovery company announced today the establishment of a wholly owned U.S. subsidiary, and the opening of a new R&D office in Cambridge, Massachusetts. This development is part of the company’s larger vision to build an innovative and globally integrated technology-driven virtual pharma company. Cambridge, MA, has long been ...continued